This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Carlo and Baker cover the latest developments after a devastating tornado outbreak over the weekend, plus an eye on Omicron and inflation, and not even Spielberg can save the box office.
Reusable rocket developer Stoke Space Technologies raised $65 million in a Series A round led by Breakthrough Energy Ventures, a firm founded by Bill Gates. Stoke says its reusable rockets provide the satellite industry with low-cost, on-demand access to and from orbit. As companies like SpacX and Blue Origin are also making commitments to rocket reusability, Stoke says it is taking a different approach with a system designed to be 100% reusable, comprised of rockets designed to fly daily, like an airplane. Stoke co-founder and CEO Andy Lapsa joins Cheddar News' Closing Bell to discuss.
Humans are set to return to a place we have not been in nearly 50 years: the moon. NASA's Artemis program is expected to have astronauts back on the lunar surface by 2025. NASA says it will use what it learns on the moon to take the next giant leap - sending the first astronauts to Mars. The Artemis program also includes contributions from private companies like SpaceX, as well as academic research institutions like Georgia Tech. Georgia Tech professor of practice and former NASA astronaut Sandra Magnus joins Future of Space: Humankind's Leap Forward to discuss.
The CDC warns that COVID-19 is rapidly spreading with Omicron variant cases doubling every two days in the United States. How do current vaccines hold up against the new strain, and what does it mean for your upcoming holiday travel? Cheddar News breaks things down with infectious diseases specialist Dr. William Schaffner of Vanderbilt University School of Medicine.
President Joe Biden is expected to meet with his COVID-19 response team as the omicron variant continues to surge across the country. Experts say Delta is driving this surge but Dr. Anthony Fauci says Omicron will take over. Emergency physician Dr. Daniel Fagbuyi joins Cheddar News to discuss.
Omicron is on course to become the dominant COVID strain in the U.S., even as Delta is causing another spike in cases. According to Johns Hopkins University data, cases across the country are up 40% from last month, with New York City as a major hotspot. Outbreaks are now causing Broadway performances to be canceled, colleges and universities to shift to online classes, sports leagues to postpone games, and more. Dr. Jen Caudle, family physician and associate professor at Rowan University, joined Cheddar to discuss the surge in cases and how we can best protect ourselves against the new variant.
